Direct comparison with the incidence of P53-MYC defects in our own large cohort (n = 344) of uniformly characterized primary medulloblastomas, sampled and subgrouped at diagnosis, showed significant enrichment of these combined defects in relapsed MBSHH subgroup tumors following treatment with standard chemotherapy and radiotherapy (60% [three of five] versus 12% [eight of 65] at diagnosis [p = 0.0250, Figure 2B]). Here, TP53 is linked to medulloblastoma.